证券代码：688389 证券简称：普门科技 公告编号：2023-040 深圳普门科技股份有限公司 第二届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 深圳普门科技股份有限公司（以下简称"公司"）于2023年8月23日以现场 加通讯方式召开了第二届董事会第二十二次会议。本次会议通知已于2023年8月 11日以电话、邮件、书面等形式送达公司全体董事。本次会议由董事长刘先成先 生主持，会议应参加董事8人，实际参加董事8人。本次会议的召开符合有关法律 法规和《深圳普门科技股份有限公司章程》的相关规定。 二、董事会会议审议情况 经全体董事表决，形成决议如下： （一）审议通过《关于〈公司2023年半年度报告〉及其摘要的议案》 董事会认为：《公司2023年半年度报告》的编制和审议程序符合法律、行政 法规及《公司章程》等有关规定；《公司2023年半年度报告》的内容和格式符合 中国证监会和上海证券交易所的有关规定，客观公允地反映了报告期内财务状况 和经营成果等事项；半年度报告编制过程中 ...

一、监事会会议召开情况 深圳普门科技股份有限公司（以下简称"公司"）于2023年8月23日以现场方 式召开了第二届监事会第二十次会议。本次会议通知已于2023年8月11日以电话、 邮件、书面等方式送达公司全体监事。本次会议由监事会主席刘敏女士主持，会 议应参加监事3人，实际参加监事3人。本次会议的召集、召开符合《中华人民共 和国公司法》等法律法规、规范性文件和《公司章程》的相关规定。 证券代码：688389 证券简称：普门科技 公告编号：2023-041 深圳普门科技股份有限公司 第二届监事会第二十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、监事会会议审议情况 经与会监事审议，做出以下决议： （一）审议通过《关于〈公司2023年半年度报告〉及其摘要的议案》 经审核，监事会认为：《公司2023年半年度报告》的编制和审议程序符合法 律、行政法规及《公司章程》等有关规定；《公司2023年半年度报告》的内容和 格式符合中国证监会和上海证券交易所的有关规定，客观公允地反映了报告期内 财务状况和经营成果；半年度 ...

证券代码:688389 证券简称:普门科技 深圳普门科技股份有限公司 2023 年股票期权激励计划(草案） 深圳普门科技股份有限公司 二零二三年八月 1 声 明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或权益行使安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激励计划 所获得的全部利益返还公司。 特别提示 一、本激励计划系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上海证券交易所科创板股票上市规则》《上市公司股权激励管理办法》《科创板 上市公司自律监管指南第 4 号——股权激励信息披露》等其他有关法律法规、规范 性文件，以及《深圳普门科技股份有限公司章程》制订。 二、本激励计划采取的激励工具为股票期权。股票来源为深圳普门科技股份有 限公司（以下简称"公司"或"本公司"）向激励对象定向发行公司 A 股普通股股 票。 三、本激励计划拟向激励对象授予 809 万份股票 ...

深圳普门科技股份有限公司 关于召开2023年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 8 月 25 日（周五）至 8 月 28 日（周一）16:00 前登 录上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 bod@lifotronic.com 进行提问。公司将在业绩说明会上对投资者关注的问题进行 回答。 一、说明会类型 深圳普门科技股份有限公司（以下简称"公司"）已于2023年8月25日在上 海证券交易所网站（www.sse.com.cn）披露了《深圳普门科技股份有限公司2023 年半年度报告》，为加强与投资者的深入交流，便于广大投资者更全面、深入地 了解公司情况，公司拟以网络互动形式召开2023年半年度业绩说明会，欢迎广大 投资者积极参与。 二、说明会召开的时间、地点 本次业绩说明会将于2023年8月29日（周二）上午10:00-11:00在上证路演中 心（https://roadshow.sseinfo.com）以网络互动的方式召 ...

深圳普门科技股份有限公司 2023 年股票期权激励计划授予激励对象名单 一、股票期权激励计划的分配情况汇总表 | 激励对象 | 获授股票期权数量 | 约占授予股票期权 | 约占公告日股本总 | | --- | --- | --- | --- | | | （万份） | 总数比例 | 额比例 | | 一、技术骨干、业务骨干 | | | | | 共 188 人 | 809 | 100% | 1.90% | | 合计 | 809 | 100% | 1.90% | 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未超过公司总 股本的 1%。公司全部有效的激励计划所涉及的标的股票总数累计不超过股权激励计划提交股东大会时公 司股本总额的 20%。 2023 年 8 月 25 日 2、本计划的激励对象不包括独立董事、监事、单独或合计持有上市公司 5%以上股份的股东或实际控 制人及其配偶、父母、子女。以上激励对象包括 1 名中国香港籍人士（曾麟贵）及 2 名外籍人士（ASIM FAIQ、ANGEL YIGON ZHENG ZHENG）。 3、以上合计数据与各明细数相加之和在尾数上有差异是由于四舍五 ...

2023 年第一季度报告 证券代码：688389 证券简称：普门科技 深圳普门科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 (一)公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 (二)公司负责人刘先成、主管会计工作负责人及会计机构负责人（会计主管人员）王红保证季度 报告中财务信息的真实、准确、完整。 (三)第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (四)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 277,799,957.78 | 32.29 | | 归属于上市公司股东的净利润 | | 88,108,225.27 | 31.23 | | 归属于上市公司股东 ...

Financial Performance - The company achieved total revenue of 983.04 million yuan in 2022, representing a year-on-year growth of 26.34%[4] - Net profit attributable to the parent company was 251.50 million yuan, an increase of 32.12% year-on-year[4] - The operating cash flow reached 271.71 million yuan, showing a significant growth of 49.24% compared to the previous year[4] - The compound annual growth rate (CAGR) for revenue from 2016 to 2022 was 33.39%, while net profit grew at a CAGR of 40.02% during the same period[9] - The basic earnings per share for the year was 0.60 yuan, reflecting the company's strong financial performance[4] - The company reported a cash dividend amount of 100,061,400.00 RMB, which represents 39.79% of the net profit attributable to ordinary shareholders in the consolidated financial statements[100] - The company has established a profit distribution policy that mandates a minimum cash dividend ratio of 80% for mature stages without significant capital expenditure plans[117] - The proposed cash dividend distribution is RMB 2.37 per 10 shares, totaling RMB 100,061,400 based on a total share capital of 422,200,000 shares as of December 31, 2022[123] - The company achieved a net profit available for distribution of positive value, ensuring that cash dividends will not affect future operations[154] - The company has a strong cash flow position, allowing for potential cash dividends while maintaining operational sustainability[154] Business Strategy and Market Position - The company is focusing on product differentiation strategies in the in vitro diagnostics and rehabilitation sectors, despite global challenges such as chip shortages and geopolitical tensions[12] - The company aims to build a platform enterprise capable of expanding across multiple product areas and markets, enhancing its value proposition for stakeholders[12] - The company ranked 15th among medical device manufacturers in terms of revenue, advancing 10 positions from the previous year[29] - The company was listed as 415th in the "Top 500 New Economy Enterprises in China" ranking[29] - The company is focused on expanding its market presence and enhancing its product offerings in the field of medical technology[156] - The company is actively pursuing import substitution strategies to enhance its competitive position in the industry[199] - The company is focusing on expanding its domestic and international business revenue through new product certifications and market entry strategies[199] Research and Development - The company is focusing on developing core technologies in in vitro diagnostic products, including electrochemical luminescence platforms and various testing reagent series[36] - The company plans to continue investing in R&D, leveraging the opening of its headquarters to attract high-end talent in medical device development[119] - The company is actively involved in research and development of new products and technologies in the medical diagnostics sector[156] - The company added 43 new domestic and international registration/filing certificates in the in vitro diagnostics field during the reporting period[9] - The company obtained 27 registration certificates for biochemical reagent products, enhancing its product line in the in vitro diagnostic sector[199] - The eCL9000 high-speed electrochemical luminescence immunoassay analyzer was launched, achieving a testing speed of 300 tests per hour, with the capability to expand to 1200 tests per hour through modular design[199] - The company has made significant investments in research and development to support the launch of new products and technologies[199] Corporate Governance and Compliance - The company adheres to principles of fairness and transparency in investor relations management, ensuring effective communication with investors[52] - The company ensures compliance with all legal and regulatory requirements for its overseas sales, including product quality certification and customs import permits[62] - The company has not reported any violations regarding guarantees or significant accounting errors during the reporting period[65][66] - The company has a commitment to not engage in illegal related-party transactions that could harm the interests of the company and its shareholders[62] - The company has established a clear commitment to maintaining a stable controlling shareholder and actual controller during any share reduction activities[62] Employee and Organizational Development - Employee stock ownership numbers stand at 72, representing 5.24% of the total workforce, with a total of 9,246.49 thousand shares held[49] - The company has established a talent development center to provide vocational training for new and existing employees, aiming to enhance work capabilities and efficiency[78] - The company emphasizes the importance of employee development through various training programs, including management training and performance coaching[78] - The company has implemented a performance evaluation system for its management team, focusing on operational revenue, business costs, and profit indicators, with annual targets set and assessed by the board[67] - The company strictly adheres to labor laws, providing competitive compensation packages that include fixed and variable salaries linked to performance, along with various non-monetary benefits[78] - The company has a commitment to gender equality in hiring and employment practices, ensuring equal opportunities and fair compensation for all employees[78] Social Responsibility and Sustainability - The company emphasizes the importance of social responsibility and has implemented a comprehensive party-building system to guide its development[51] - The company has committed to reducing carbon emissions by 408 tons through various measures, including utilizing solar energy resources and actively constructing photovoltaic power generation projects with an average annual output of approximately 408,800 kWh[73] - The company has conducted ESG training for all mid-to-senior management personnel to integrate ESG concepts into daily operations[69] - The company actively protects consumer rights by managing customer service effectively and providing product knowledge training to frontline staff[78] - The company has established a customer information protection system to safeguard client data and enhance employee awareness of information security[78] Operational Efficiency - The company aims to enhance management efficiency and execution by adjusting its organizational structure and improving financial data analysis capabilities[40] - The company emphasizes the importance of a robust marketing system and has implemented a CRM system to enhance customer relationship management[101] - The company is committed to strengthening its human resources management system to support the growth of its talent pool[101] - The company has established a robust operational framework to support its growth strategy and market expansion initiatives[156] - The company aims to enhance its information technology capabilities to improve operational efficiency and create a more intelligent working environment[103]

证券代码：688389 证券简称：普门科技 公告编号：2023-015 深圳普门科技股份有限公司 关于召开2022年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1.会议召开时间：2023年5月17日（周四）11:00-12：00 2.会议召开地点：上证路演中心（http://roadshow.sseinfo.com） 3.会议召开方式：网络互动 三、参加人员 公司董事长刘先成先生，董事、总经理胡明龙先生，董事、副总经理曾映先 生，董事、副总经理李大巍先生，董事、副总经理邱亮先生，董事、财务总监、 董事会秘书王红女士。（如有特殊情况，参会人员将可能进行调整） 四、投资者参加方式 1.投资者可于2023年5月17日（周四）11:00-12：00登录上证路演中心 （http://roadshow.sseinfo.com），在线参与本次业绩说明会。 4.投资者可于2023年5月10日(星期三)至5月16日(星期二)16:00前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱bo ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥226,590,025.83, representing a year-over-year increase of 20.54%[7] - The net profit attributable to shareholders for Q3 2022 was ¥53,567,277.08, reflecting a growth of 34.53% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥50,321,336.91, which is an increase of 58.98% year-over-year[11] - The basic earnings per share for Q3 2022 was ¥0.12, up by 33.33% from the previous year[11] - The net profit attributable to shareholders for the year-to-date period reached ¥153,067,473.19, with a year-over-year increase of 25.22%[7] - Total operating revenue for the first three quarters of 2022 reached RMB 673,438,420.05, an increase of 23.7% compared to RMB 544,056,045.76 in the same period of 2021[49] - Net profit for the first three quarters of 2022 was CNY 152,955,946.85, compared to CNY 122,106,061.14 in 2021, representing a year-over-year increase of about 25.3%[56] - The company reported a total operating profit of CNY 161,986,079.65, up from CNY 129,401,543.53 in the previous year, indicating a growth of around 25.2%[56] - The company’s total profit for the first three quarters of 2022 was CNY 161,787,111.93, compared to CNY 129,142,231.34 in 2021, representing a growth of about 25.3%[56] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥1,735,199,311.80, marking a 17.68% increase from the end of the previous year[11] - Current assets as of September 30, 2022, amounted to RMB 1,159,797,739.38, up from RMB 1,010,296,053.05 at the end of 2021, reflecting a growth of 14.7%[44] - Total assets reached RMB 1,735,199,311.80, up from RMB 1,474,453,581.25, indicating a growth of 17.7%[49] - The company's total liabilities as of Q3 2022 were ¥460,619,787.82, compared to ¥327,021,998.91 in Q3 2021, showing a significant increase[66] - Total liabilities increased to RMB 390,609,213.66 from RMB 216,501,445.41, reflecting an increase of 80.5%[49] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥108,548,182.62, which is a 33.53% increase compared to the same period last year[11] - Net cash flow from operating activities for the first three quarters of 2022 was ¥170,055,461.30, significantly up from ¥37,366,942.25 in 2021, indicating a growth of about 354.5%[74] - Cash inflow from operating activities totaled ¥882,730,464.50 in 2022, compared to ¥563,036,800.77 in 2021, marking an increase of approximately 56.7%[74] - Cash outflow from operating activities was ¥712,675,003.20 in 2022, up from ¥525,669,858.52 in 2021, reflecting a rise of about 35.5%[74] - Cash outflow from investing activities totaled CNY 164,867,714.18, compared to CNY 201,675,186.10 in the previous year, indicating a decrease of approximately 18.3%[60] Research and Development - Research and development expenses totaled ¥47,326,232.19 in Q3 2022, accounting for 20.89% of operating revenue, a decrease of 4.09 percentage points year-over-year[11] - Research and development expenses increased to CNY 139,218,794.69 in 2022 from CNY 118,078,823.31 in 2021, marking a rise of approximately 17.9%[58] - Research and development expenses for the first three quarters of 2022 were ¥100,345,503.72, up from ¥86,527,335.74 in the same period of 2021, representing a 16% increase[68] Product Development and Market Performance - The company has registered 2 new products in the electrochemiluminescence technology platform, enhancing its core competitiveness in this field[30] - The company has achieved significant performance in overseas markets, particularly in high-performance liquid chromatography technology, with 1 new product registration[30] - The company has upgraded its treatment and rehabilitation product line, introducing the LC-580 extracorporeal shock wave therapy device, which can be widely used in various medical institutions[31] - The company has officially entered the endoscope field by acquiring a controlling stake in Shenzhen Zhixin Biomedical Technology Co., Ltd., enhancing its treatment and rehabilitation product line[32] - Two of the company's products were selected for the "Excellent Domestic Medical Equipment Product Directory," showcasing its innovation capabilities[36] Strategic Initiatives - The implementation of a Customer Relationship Management (CRM) project is expected to enhance the company's marketing efficiency and customer management capabilities[37] - The company is in the trial phase of a product line management and R&D transformation project, aiming to improve product development quality and efficiency[38] - The company has successfully launched the Supply Chain Relationship Management (SRM) project, enhancing supply chain efficiency and reducing operational risks[39] - The headquarters building project has reached a significant milestone with the completion of the main structure, expected to improve the working environment and company image[40] Recognition and Awards - The company was listed in the "Top 500 New Economy Enterprises in China," reflecting its continuous innovation and market recognition[35]

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 20%[2] - The company expects a revenue growth of 25% for the full year 2022, projecting a total revenue of 1.2 billion RMB[2] - The company's operating revenue for the first half of 2022 was RMB 446,848,394.22, representing a year-on-year increase of 25.49% compared to RMB 356,076,468.66 in the same period last year[27] - The net profit attributable to shareholders of the listed company was RMB 99,500,196.11, up 20.72% from RMB 82,425,189.86 in the previous year[27] - The net cash flow from operating activities rose by 39.06%, amounting to RMB 90,627,557.37, primarily due to increased sales collections[31] - The basic earnings per share for the first half of 2022 was RMB 0.24, a 20.00% increase from RMB 0.20 in the same period last year[30] - The total assets at the end of the reporting period were RMB 1,611,841,195.63, reflecting a year-on-year increase of 9.32%[27] - The net assets attributable to shareholders at the end of the reporting period were RMB 1,284,583,755.10, an increase of 2.32% compared to the previous year[27] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2023[2] - The company attributed revenue growth to the enhancement of its two main product lines and improved marketing capabilities in domestic and international markets[31] - The company has identified opportunities for market expansion in diagnostic products and home healthcare devices, aligning with consumer preferences[42] - The company is positioned to benefit from favorable policies and market trends, indicating potential for future revenue growth[42] Research and Development - Research and development expenses increased by 15%, totaling 75 million RMB, focusing on innovative healthcare solutions[2] - The R&D investment accounted for 20.56% of operating revenue, up from 19.97% in the previous year[30] - R&D expenses for the first half of 2022 amounted to CNY 91.89 million, a 29.20% increase compared to CNY 71.12 million in the same period last year[141] - The company has established multiple R&D platforms, including the "Academician Workstation" and "Shenzhen Engineering Laboratory," enhancing its overall R&D capabilities[180] - The company has developed 13 testing packages for tumor markers, inflammation, myocardial markers, thyroid function, sex hormones, and coagulation/thrombosis based on the electrochemical luminescence detection platform[146] Product Development and Innovation - New product launches include a cutting-edge diagnostic device expected to contribute 10% to total revenue in the next quarter[2] - The company successfully developed a new generation of fully automated immunoassay platforms, breaking the global monopoly of international giants in the electrochemical luminescence immunoassay field and filling a domestic market gap[58] - The company launched a new generation of high-speed glycosylated hemoglobin analyzers and supporting reagents, significantly improving instrument performance and detection throughput[119] - The company has developed a disposable negative pressure dressing that meets clinical treatment needs, filling a significant gap in its wound treatment product line[116] - The company has introduced new products in the treatment and rehabilitation sector, including a series of devices aimed at preventing and treating deep vein thrombosis[101] Industry Trends and Challenges - The medical device industry in China is experiencing growth, driven by increasing health demands and an aging population, suggesting a favorable market outlook[42] - The medical device industry faces challenges such as low industry concentration and weak innovation capabilities, which the company may need to address[42] - The demand for high-end medical devices is increasing, with a focus on enhancing domestic production capabilities and reducing reliance on imports[48] - The industry faces challenges related to funding, as high development costs and long product cycles create significant financial barriers for new entrants[55] Regulatory and Compliance - The company has established a quality management system certified by TÜV Rheinland, ensuring compliance with ISO13485 standards and enhancing product quality for entry into developed markets[188] - The company has completed EU registration for 187 products, including IVD products and rehabilitation treatment products, and has received CE certification for a COVID-19 antigen test kit[125] Customer Engagement and Support - The company has implemented a comprehensive after-sales service system with 104 experienced service personnel, ensuring 24/7 support and high customer satisfaction[192] - The company has conducted 75 business training sessions during the reporting period, with 2,268 participants, improving customer recognition of its products and increasing equipment usage efficiency[193] Financial Health and Investment - The company has increased its R&D investment in the in vitro diagnostic product line, launching new products that enhance its competitive edge in the market[199] - The company has optimized its supply chain management, implementing MTO and MTS delivery strategies to effectively meet market demands and reduce delivery risks[189]